Boston Venture Forum Program and Speakers
- Written by civf
- January 19, 2012 at 10:21 pm
- June 21, 2012
- 8:45 am - 9:30 amRegistration, Continental Breakfast and Networking
- 9:30 am - 9:45 amOpening RemarksMartin Duchaine, Capital Innovation
- 9:45 am - 11:00 amVenture Capital and Strategic Investor PanelModerated by Samuel Shafner, Burns & Levinson
- 11:00 am - 11:30 amNetworking Break
- 11:30 am - 12:30 pmInnovative Entrepreneur Presentations
- 12:30 pm - 2:30 pmLuncheon Panel of Merck, Lumira and Teralys discussing recent LP investment in 2 Lumira funds
- 2:00 pm - 4:00 pmInnovative Companies Presentations
- 4:00 pm - 7:00 pmNetworking Cocktail and Introduction to the New England Investors Committee
Samuel M. Shafner PartnerBurns & Levinson LLPSamuel M. Shafner has concentrated his practice exclusively in the area of transactional corporate and securities law for more than twenty years. Mr. Shafner has particular expertise in assisting emerging technology companies, both domestic and international, in their capital formation as well as in basic business contract needs. Most of Mr. Shafner's clients are high-technology businesses and venture capital firms specializing in high technology investments. Consequently, Mr. Shafner frequently negotiates software licenses, ...
Alain Denis Senior Vice-President - New EconomyFonds de solidarité FTQAlain Denis is a Senior Vice-President at Fonds de solidarité FTQ where he is responsible for all investments in Information Technology, Telecommunications and Life Sciences sectors. Activities includes management and growth of existing portfolio, sourcing of new investment opportunities, new partnerships and business development.
Jacques Bernier Managing PartnerTeralys CapitalJacques Bernier is a highly respected venture capitalist, entrepreneur and investor who’s helped shape the Canadian technological innovation scene. Through a 30 year career of contributions to the high-tech community, he has been actively involved in more than a dozen emerging high-tech companies as Founder/CEO or angel investor as well as Senior Vice-President of the Solidarity Fund QFL. Jacques’ widely valued wisdom and experiences continue to define, develop and implement a new approach to venture capital in Québec and abroad.
Daniel Hétu Managing DirectorLumira CapitalWith 20 years of investment banking, corporate and business development, and licensing experience, Daniel has been involved with life science companies at all stages of development in North America and overseas. Before joining Lumira Capital in 2005, Daniel located in Montréal, spent 10 years at Shire Pharmaceuticals and at Biochem Pharma prior to its acquisition by Shire as vice president, business development North America (Shire), and vice president, corporate development (Biochem Pharma). During that period, he was involved with the in-licensing of a...
Dr. Reid Leonard Executive Director, Worldwide LicensingMerck Research LaboratoriesReid Leonard is Executive Director, Worldwide Licensing for Merck & Co., Inc. Based in Boston, Massachusetts, Reid provides guidance on Merck's licensing interests to biotechnology companies, academic institutions, and venture firms. He serves as an initial contact for the scientific evaluation of partnership opportunities through which Merck may collaborate to develop novel therapeutics. Reid's area of responsibility includes the Northeastern United States and Latin America. He also supervises search and evaluation efforts in Canada and India. Dr. Leonard graduated from Brandeis Unive...
Michael Greeley General PartnerFlybridge Capital PartnersMichael is a General Partner at Flybridge Capital Partners whose principle investment focus area is the application of "Big Data" platforms across a number of industry verticals. Additionally, Michael is excited about the convergence of healthcare and information technologies, as well as robotics and human-machine interface technologies. Michael currently represents the firm on the boards of BlueTarp Financial, MicroCHIPs, PolyRemedy, Predictive Biosciences, SpringLeaf Therapeutics, T2 Biosystems, TARIS Biomedical, and VidSys. He also serves on the board of the National Venture Capital Associ...
Jack W. Lasersohn General PartnerVertical GroupMr. Lasersohn has thirty years of experience in health care venture capital investments. Prior to joining The Vertical Group's predecessor, F. Eberstadt in 1981, Mr. Lasersohn was a corporate attorney with Cravath, Swaine & Moore. Mr. Lasersohn currently serves on the Boards of Directors of Masimo Corporation, Oncomed, Photothera, Proteolix, Silk Road Medical and TetraLogic Pharmaceuticals. He previously served on the boards of Bacchus Vascular, CardioThoracic Systems, Inc., Cardiovascular Imaging Systems, Inc., E.P. Technologies, Integrated Vascular Systems, and Kyphon Inc . Mr. Lasersohn...
Cat Oyler Senior Director of Emerging TechnologiesJohnson & JohnsonCat Oyler is Sr. Director, Emerging Technologies in the Corporate Office of Science and Technology at Johnson & Johnson. Based in Boston, Massachusetts, Cat is responsible for identifying and nurturing emerging health care related technologies in the New England area, assessing technical and business risk of the new technologies, and facilitating integration of these technologies into the Johnson & Johnson Family of Companies and their product lines. In this role, Cat works with local area faculty, researchers, entrepreneurs, and investors to identify innovative product/business opport...
Greg Madden Portfolio ManagerSV Life SciencesSummary: Greg Madden joined SVLS in 2002 and focuses on transactions and monitoring of portfolio companies. Secondly, Greg spearheads the firm’s investor relations and fundraising activities. Greg’s current and past deal assignments include: Achillion Pharmaceuticals (ACHN), AcuFocus, Alliancecare, Auxilium Pharmaceuticals (AUXL), CardioFocus, CHF Solutions, Concentric Medical, Ikano Therapeutics, Insulet (PODD), LenSx Lasers, NeoVista, NeurogesX (NGSX), and Orchid Pharmaceuticals (ORCD). Prior Experience: Prior to joining SVLS, Greg worked at Testa, Hu...
Jeffrey B. Moore Vice PresidentMP Healthcare Venture ManagementJeff Moore is Vice President of MP Healthcare Venture Management (MPH). Previously, Dr. Moore was a Kauffman Fellow with the early stage venture capital firm Research Corporation Technologies. He has held various business and scientific roles at Millennium Pharmaceuticals and Scriptgen/Anadys. He received his DPhil from Oxford and postdoctoral training at Harvard. Dr. Moore received his MBA as a Sloan Fellow at MIT. MPH is a Boston-based lifesciences venture capital firm investing in seed to late stage companies developing innovative therapeutics, platform technologies, diagnostics and vaccine...
Scott Requadt, JD, MBA PartnerClarus VenturesScott has over 10 years of operating and investment experience in the pharmaceutical industry. Prior to joining Clarus in 2005, Scott was Director, Business Development of TransForm Pharmaceuticals, Inc until it was acquired in 2005 by Johnson & Johnson. At TransForm, Scott had broad responsibility for business development, corporate development and legal activities, including managing the company’s intellectual property group. Prior to TransForm, Scott practiced for several years as an M&A attorney at the NYC-based law firm of Davis Polk & Wardwell, where he represented numer...
- June 21, 2012